The two other mutations predicted as deleterious, ARHGEF5 and SMTNL2, are linked to a poor prognosis in lung cancer patients, epithelial-mesenchymal transition (EMT), and Rho-GTPase signaling [31,32]. Here, SMTNL2 is linked to lung carcinoma.